The Risk–Benefit Analysis of Menopausal Hormone Therapy in the Menopause

doi:10.1017/9781108869102.024

Chapter 23 - The Risk–Benefit Analysis of Menopausal Hormone Therapy in the Menopause

Published online by Cambridge University Press: 18 June 2020

Elizabeth Stephenson and

Edited by

Paula Briggs and

Nicholas Panay: Affiliation:
Queen Charlotte's & Chelsea Hospital, London
Paula Briggs: Affiliation:
Liverpool Women's NHS Foundation Trust
Gabor T. Kovacs: Affiliation:
Monash University, Victoria

Book contents

Get access

Summary

The menopausal hormone therapy (MHT) risk–benefit profile has been at the centre of the debate that polarizes opinion between those who advocate the use of MHT and those who oppose it even before the publication of the original Women‘s Health Initiative (WHI) study in 2001. Whilst there is broad agreement around some of the key benefits of MHT there remains considerable difference about the interpretation of the risks in taking it. Revised data from the WHI and other randomized clinical trials since the publication of WHI together with various recent authoritative international position statements and recommendations since the last edition have helped to clarify some of the uncertainties and provide more robust evidence for clinical decision-making.

Type: Chapter
Information: Managing the Menopause , pp. 234 - 245

DOI: https://doi.org/10.1017/9781108869102.024 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Shufelt, C, Bairey Merz, CN. Reassurance for many Healthy Women Considering HRT. BMJ 2017;359:4652.CrossRef Google Scholar PubMed

Baber, RJ, Panay, N, Fenton, A. IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19(2):109–50.Google Scholar

Menopause: diagnosis and management NICE guideline [NG23]. November 2015. www.nice.org.uk/guidance/ng23 Google Scholar

Avis, NE, et al. Duration of menopausal vasomotor symptoms over the menopause transition study of Women’s Health. JAMA Intern Med 2015;175(4):531–9.Google Scholar

Maclennan, AH, Broadbent, JL, Lester, S, Moore, V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4.Google Scholar

Pitkin, J. Urogenital atrophy. British Menopause Society consensus statement. Post Reprod Health 2018;24(3):133–8.CrossRef Google Scholar

Davis, S, Baber, R, Panya, N, et al. Global Position Statement on the use of testosterone therapy for women. Climacteric 2019;104:4660–6.Google Scholar

Santen, RJ, Allred, DC, Ardoin, SP, et al. Postmenopausal hormone therapy: an Endocrine Society Scientific statement. J Clin Endocrinol Metab 2010;95:S7–66.Google Scholar

Boardman, HMP, Hartley, L, Eisinga, A, Main, C, Roquéi, , Figuls, M, Bonfill Cosp, X, Gabriel Sanchez, R, Knight, B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev 2015;3.Google Scholar

Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 2019. doi 10.1016/S0140–6736(19)31709-XGoogle Scholar